In The Know-April 2020

April 2020

Pdf Summary

Ed’s List April 2020 is a compilation of abstracts related to the field of gynecologic oncology. It includes research on ovarian cancer characteristics, screening, diagnosis, and treatment. Some of the key findings include:<br /><br />- A blood test has been developed that can detect cancer in individuals with no history or symptoms of cancer. However, the test is still experimental and requires further validation.<br />- OCAMs (ovarian cancer-associated mesothelial cells) have been found to induce acquired platinum resistance in ovarian cancer cells through cell-to-cell crosstalk. Targeting OCAMs may be a potential therapeutic strategy.<br />- Whole-exome sequencing of ovarian cancer families has identified new putative predisposition genes, ANKRD11 and POLE, which may increase ovarian cancer risk.<br />- The ARIEL3 trial showed that rucaparib maintenance treatment improved post-progression outcomes and provided lasting clinical benefits in patients with ovarian cancer.<br />- MRCKA has been identified as a potential therapeutic target in high-grade serous ovarian carcinoma.<br />- Universal tumor DNA BRCA1/2 testing of all newly diagnosed ovarian cancer patients can increase the identification rate of patients who may benefit from PARP inhibitor therapy.<br /><br />These findings contribute to our understanding of ovarian cancer and may have implications for future research and clinical practice in the field of gynecologic oncology.

Keywords

gynecologic oncology

ovarian cancer

blood test

platinum resistance

predisposition genes

maintenance treatment

therapeutic target

BRCA1/2 testing

PARP inhibitor therapy

clinical practice